(Q57651693)

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Trends in infectious diseases mortality in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Trends in Infectious Disease Hospitalizations in the United States, 1980-1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

The changing face of epidemiology of invasive fungal disease in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Nonsporulating clinical isolate identified as Petromyces alliaceus (anamorph Aspergillus alliaceus) by morphological and sequence-based methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Recent advances and challenges in the treatment of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia–forming moulds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Has antifungal susceptibility testing come of age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

EUCAST breakpoints for antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Breakpoints for susceptibility testing should not divide wild-type distributions of important target species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Comparison of the Vitek 2 antifungal susceptibility system with the clinical and laboratory standards institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Reliability of the WIDERYST susceptibility testing system for detection of in vitro antifungal resistance in yeasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3

Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-012-0100-3